Maine Opioid Clinical Advisory Committee Clinical Guidance Documents
The Maine Opioid Response Clinical Advisory Committee consists of approximately 30 leaders in substance use disorder prevention, treatment, and harm reduction in Maine. As part of its efforts, the Committee has developed clinical guidance documents on several key topics that are intended to assist Maine clinicians who care for patients with substance use disorders. These recommendations are intended to enhance clinical care and should not replace the clinical judgment of individual clinicians. These documents are generally posted on the Governor’s Office of Policy, Innovation and the Future (GOPIF) Opioid Response webpage (under “Reports & Background Documents”) and include the following:
- Proposed Position on the Use of Buprenorphine-Naloxone in Pregnancy (March 2020)
- Proposed Position on the Perioperative Management of Patients Prescribed Buprenorphine for Opioid Use Disorder (OUD) (August 2020)
- Proposed Position on Fentanyl Toxicology Testing (August 2023)
- Treatment of Co-Occurring Stimulant Use Disorder in Patients with Opioid Use Disorder (OUD) (October 2020)
- Updated MaineCare Coverage and Prior Authorization for Buprenorphine (July 2021)
- Important Updates to MaineCare Coverage and Prior Authorization Criteria for Buprenorphine for Treatment of Opioid Use Disorders
- MaineCare Prior Authorization Form #20100 for Buprenorphine/Naloxone and Monoproduct Buprenorphine
- Frequently Asked Questions: MaineCare / Change Health Care Prior Authorization Processes for Buprenorphine for Treatment of Opioid Use Disorder
- Proposed Position on Ensuring Access to Medications for Opioid Use Disorder (MOUD) in Post-Acute Care Facilities (November 2021)
- Proposed Position on Enhancing Access to Extended-Release Buprenorphine for Patients with Opioid Use Disorder (May 2022)
- Proposed Position on Promoting Medications for Opioid Use Disorder (MOUD) in Hospital Settings (February 2023)